
Similar Posts

An $800 Head Cold? Time to Fight for Price Transparency in American Healthcare
Jay Singh had a nasty head cold. Not a “will-I-survive-this-plague” kind of infection, but also not one he thought, if left to its own devices, would blow over in a day or two. So he went to the primary care clinic near his exurban New York City home. The doctor spent ten minutes examining and…
Doctors Urged to Talk About Costs of Treatment
Physicians need to broach discussions about out-of-pocket costs with patients the same way they discuss a treatment’s side effects, public policy professors wrote. “Admittedly, out-of-pocket costs are difficult to predict, but so are many medical outcomes that are nevertheless included in clinical discussions,” Peter Ubel, MD, of Duke University’s School of Public Policy, and colleagues wrote….
Newsweek Tackles the Challenge of Money Talk
In response to the New England Journal article I published with Yousuf Zafar and Amy Abernethy, Newsweek chimed in this week with a report on the topic, including some thoughtful commentary from other medical experts. I thought it was worth pointing you towards this article, in part to remind you that Newsweek still exists, and…

Medicare Drug Coverage Is Often Inadequate—Here’s Why
Your father’s rheumatoid arthritis medicine was working well, fighting off that otherwise debilitating illness. Then he found out that Medicare would no longer pay for the drug. Your aunt’s multiple sclerosis was flaring and her neurologist recommended a promising new treatment. But she learned that she would have to try, and “fail,” on two other…

What Higher Ed Can Learn From Health Care
Check out my recent interview with The Chronicle of Higher Education about the rising costs of education and healthcare: For decades, higher education has come under public scrutiny for rising costs. But there is at least one other sector that seems to feel even more heat from policy makers and ire from the public. That…
Millions To Be Made On…Generic Drugs?
It is well accepted among health economics wonks that the lion’s share of pharmaceutical company profits come when these companies hold exclusive rights to their products. Once their blockbuster pills go “generic,” competitors enter the marketplace and profits plummet. Consider captopril, a groundbreaking heart failure medication introduced in the early 80s by Bristol-Myers Squibb under…